Actinium Pharmaceuticals Inc (ATNM) 시세

I have followed ATNMs lead development for years. Fortunate to not be loaded up like I once was
when the fda screwed them over with their denial of their approval efforts. Thats going to set them
back a couple of years to get another trial composed, initiated, ran and data scrubbed. Not to mention
bleed them of the cash they have.

Couple that with where their other developments are in their pipeline? ATNM is either going to need a
partner (which has already been mentioned) or is going to be selling a lot of shares to raise cash in order
to fund their developments.

And again, they are looking at 2 years or so before they will be able to bring their first
development back to the fda.

This had so much promise.. Now?? One has to ponder the question of, did some
big pharma decide they want to be able to buy ATNM for pennies on the dollar?? For their
cancer related developments?? And the best way to do it was to delay a revenue stream
from occurring. (yeah, I know this sounds a little over the edge, but have seen enough to
no longer discount things like this when 'money' is involved)

Thought I was. China banned exports of minerals containing specific elements like Germanium. The list with story was on TV screen for too short a time, and prevented my reading entire list of elements. I haven't searched elsewhere for that list to see whether ATNM was included. I sold our ATNM shares last week to record a LTCL against LTCGs already accrued for 2024. Time to accumulate ATNM shares now, in anticipation of potential buyout for pipeline of ATNM solid or ion uses?

??? Are you on the 'right' page for this question of yours??

https://www.actiniumpharma.com/

Has ATNM again(?) become a banned mineral export by China politicians?

Has ATNM again(?) become a banned mineral export by China politicians?

Moreover

https://newscenter.lbl.gov/2024/07/15/caught-in-the-actinium/

https://cen.acs.org/physical-chemistry/nuclear-chemistry/First-actinium-crystals-reveal-unique/102/web/2024/07

One day this will take off. So looking forward to RFK Jr. kicking butt and cleaning house among the govt. "health professionals".

Technology providing a low-cost, commercial scale option to secure Ac-225 supply

Actinium’s 5 US issued patents and 49 Ex-US patents and extensive knowledge covers:

Methods of purification and recycling of Ra-226 from a variety of different sources
Target design and preparation of Ra-226 targets for proton irradiation via a cyclotron
Production and purification of Ac-225 from irradiated Ra-226 targets free of Ac-227

Actinium has developed an end-to-end solution with demonstrated commercial scalability up to 100 mCi per batch

Estimated COGS including CapEx and operational costs for a single cyclotron facility of $650 - $1,000* / mCi, less than 10-20x pricing for currently available material
For a program treating 1,000 patients per year this would translate into cost savings of greater than $10 million each year

Got ATNM on my list of 'ones to monitor' cause its not going anywhere for a while.

What a frigging screw job both the company and shareholders just had to deal with.

If nothing else, the fda could have admitted ATNMs development HELPED people
who were dealing with cancer. And told them to do a PH 4 to address the fdas
concerns.

But nope, instead they prevented something that demonstrated it helped people
from being used.

Unfricking real.. that they would do this when the development showed it was safe to use
and could help folks.

Patented technology:
https://www.actiniumpharma.com/actinium-225-technology

I only own one handful of shares just to monitor this stock. It appears oversold since the FDA hit job. The company will make good use of their new addition. I will add some at this level.

Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors
November 04 2024 - 7:30AM
PR Newswire (US)
Alert
Print
Tweet Share On Facebook

- Dr. Almenoff brings more than 25 years of drug development and leadership
experience to the Actinium Board of Directors

- Dr. Almenoff to join Actinium's Nominating and Corporate Governance Committee

NEW YORK, Nov. 4, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced the appointment of June Almenoff, M.D., Ph.D. to its Board of Directors. Dr. Almenoff is an accomplished biopharma executive with over 25 years of senior leadership and drug development experience. She currently serves as a Board Director and advisor to numerous biopharma companies.

(PRNewsfoto/Actinium Pharmaceuticals, Inc.)

Andes Seth, Actinium's Chairman and CEO, stated, "Through her career, June has amassed significant experience in translational research, drug development and business development that has resulted in multiple approved products and value creation. Her experience will be invaluable to Actinium and we are delighted to add Dr. Almenoff to the Actinium Board."

Dr. Almenoff served as President and Chief Medical Officer of Furiex Pharmaceuticals, which was acquired by Actavis plc (now AbbVie) for $1.2B. Furiex developed eluxadoline (Viberzi®), which was approved both in the United States and Europe. She also served as Chief Medical Officer of RedHill Biopharma Ltd (Nasdaq: RDHL) leading a team whose work led to the recognition of Talicia® as a first-line therapy for H. pylori. Earlier in her career, Dr. Almenoff was at GlaxoSmithKline (GSK) for 12 years, where she held various positions of increasing responsibility. She was a Vice President in the Clinical Safety Organization, chaired a PhRMA-FDA working group, and worked in the area of scientific licensing. She also led the development of pioneering data analytics systems, which have been widely adopted by industry and regulators to minimize clinical risk for pharmaceutical products.

Dr. Almenoff has strong expertise in translational medicine, clinical development, commercial strategy, and business development across many therapeutic areas, and has led or contributed to numerous regulatory submissions, product approvals and launches. She is a member of the investment advisory board of the Harrington Discovery Institute, a director on the board of Avalo Therapeutics, Inc. (Nasdaq: AVTX) and Tenax Therapeutics (Nasdaq: TENX).

Dr. Almenoff added, "Targeted radiotherapy has become an important treatment option for patients in multiple oncology indications, which I believe will only continue to expand. I am impressed by Actinium's innovative R&D, clinical development experience and capabilities, as well as its proprietary Actinium-225 manufacturing technology. Collectively, Actinium has the vision and components to become a leading fully integrated specialty radiopharmaceutical company. I am excited to join the Actinium Board and look forward to working to help the company realize its vision and create value for patients and shareholders alike."

Dr. Almenoff received her B.A. cum laude from Smith College and graduated with Alpha Omega Alpha honors from the M.D.-Ph.D. program at the Icahn (Mt. Sinai) School of Medicine. She completed post-graduate medical training at Stanford University Medical Center and served on the faculty of Duke University School of Medicine. She is an adjunct professor at Duke, a Fellow of the American College of Physicians (FACP) and has authored over 70 publications.

About Actinium Pharmaceuticals, Inc.

Actinium develops Antibody Radiation Conjugates ("ARCs") and other targeted radiotherapies intended to meaningfully improve outcomes for people who have failed existing oncology therapies. Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia ("r/r AML"), which Actinium is seeking a potential strategic partner for in the U.S. The company continues to advance its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, Actinium is engaged with the National Cancer Institute ("NCI") under the Cooperative Research and Development Agreement ("CRADA") for development of Actimab-A in AML and other myeloid malignancies. Iomab-ACT, Actinium's next generation conditioning candidate, is being developed with the goal of improving patient access and outcomes for potentially curative cell and gene therapies. In addition, the company's R&D efforts are primarily focused on advancing several preclinical programs for solid tumor indications. Actinium holds more than 235 patents and patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron.

For more information, please visit: https://www.actiniumpharma.com/

Who controls the patents?

Yes sir. The FDA and Pig Pharma has a revolving door. FDA retirees then get lucrative jobs with the pigs who then use their contacts back at FDA to get insider assistance. Those back at the FDA owe their postitions to the retired X FDA haunchos working at Pig Pharma companies....same goes for NIH and CDC. They are all one big happy club. Maybe just maybe a new admin will make some much needed changes in the health system a la RFK Jr.

Yeah, but unfortunately, its going to take a good 2 years to get this 'additional trial' done.

Time line includes developing the trial, getting the fdas concurrence that it will meet their 'standards' (until it doesn't)
set up the trial sites, run it and then data scrub.

Then add on another 2 months to get the fDA to accept the NDA, 6-9 months to get a decision.

Hell, ATNM is looking at damn near 3 years before they could get a decision.

And then there is the question, how many shares are they going to have to sell to stay solvent..

Ie, there goes the $20+ target price.

What a frigging mess.

Actinium intends to further discuss the specifics of the additional clinical trial including the patient population, which the . FDA has suggested could include all adult AML patients

Well at least CRMD has worked out so far..

The SICK part of the fdas surreal decision is that
ATNMs development HELPED people. So why in the hell
didn't the fda tell ATNM, ok, approved, but run a PH 4
follow up to monitor the long term outcome. Instead of
denying people the right to use something that could
make their life better. Frigging unreal.. because its not
like this development was hurting folks in the process.

https://finance.yahoo.com/news/actinium-provides-regulatory-planned-bla-110000319.html

Last I UNDERSTAND on ATNM is that the fed death agency is going to require a NEW PH 3. Means this one is pretty much 'dead' for the next year minimum since they don't
have anything else in the pipeline. And at some point, having to see more shares to raise cash.

What a screw job the fda pulled on them based on what the company has said so far.

Thanks Timber (I think you dropped CRMD here too, my brother has some, that one’s moving of late.)Yes once ICU gets approval for ADULT aki… much bigger population. I remember them alluding to potential use for organ transplant treatment in future, and many other paths. Just looked up Ihub ICU board: https://investorshub.advfn.com/SeaStar-Medical-Holding-Corp-ICU-42335
Now back to our ATNM waiting for some good news… that brings us back to $6 then $10… :c

On ICU... only 4 or so Mil shares, thats nice to see (course they did a r/split to get there)

Bigger issue may be the SMALL population of potential patients in terms of who THEY see
as their potential 'market'..

Interesting 'development', something I am familiar with in terms of it basically being a
blood 'conditioner'. Got to look into how well it really works from the aspect of, if someone
gets this 'condition', will the facility see their development as something they HAVE to try.

On NSPR, I don't own any yet. Still watching the momentum which is weighing negative,
but the share price is resisting breaking down, holding $2.7. Was hoping it would drop to $2.50
or less...But will be getting some before their next earnings call just in case they say something along
the lines of revenues/sales in the overseas markets continues to move higher..

I learned of nspr from you here, it was a buck and I missed it as it went through $2, I hold some now but at par. Shoulda listened at $1! ICU is unique though (not ICUI) with apparent blue skies on many fronts, time factor and burn rate holding them back. https://journey.ct.events/view/7f792b7c-2391-4da5-9718-55622babdcae thanks for reply…
not for the faint of heart!

Oops, wrong company.. Meant AWE platform for attacking solid tumors...

If you are looking at something to get into, check out NSPR.. They have just submitted an application for approval for a
stent design that IS a lot better than the current technology being used. They are anticipating a decision in the 1st half of 2025.
I have traded the shares a couple of times in the past, have a 'very conservative' initial target price of $5. Which from the current
price of around $2.75, would be around a 80% POTENTIAL return IF the fda approves their medical DEVICE (not a drug). Which
is already approved overseas and is being sold/used. (but no secret, you want to generate serious revenues, you need to be approved
to sell into the US market).
Disclaimer: I don't own any at the moment, just watching to see if the share price will keep slipping off its recent highs from the news
that they submitted their application.
NOTE; will check into ICU, but from an initial quick look at what they are doing, I prefer to find companies that are doing something much better
than whats already on the market, or something NEW... AKA, ATNMs conditioner effort and still can't believe what happened to them.

https://www.actiniumpharma.com/awe-technology

Actinium's Antibody Warhead Enabling (AWE) Technology Platform
Actinium's AWE technology platform is used to produce ARCs or Antibody Radiation Conjugates, a highly potent and selective form of targeted radiotherapy. ARCs enable the precision targeting of the proven therapeutic power of radiation to tumors and its synergistic potential with other therapeutic modalities that cannot be matched by traditional external beam radiation, cytotoxic chemotherapy or biologic therapies. AWE enabled ARCs exploit the use of highly selective targeted biological agents such as monoclonal antibodies that can seek out and bind cancer antigens found on the tumor cell surface to deliver potent radioisotopes that are capable of producing double strand DNA breaks for which there is no known resistance or repair mechanisms.

Timber please, what is WAR programs?…
I tried to get a comment from ATNM investor relations on situation but no response.
also, have you looked into ICU stock? thanks

On a possible buyout. Yep, this screw job by the fda could be part of something
to corner ATNM management into doing something they weren't prepared to do.

The other question I hadn't really spent much time on yet is, just how good is their
WAR programs? How good/effective is the technology.

.

With the recent price drop the majority shareholders in ATNM may be softened up enough to accept a much lower buyout price for the company but the question is will Seth be willing to sell. If he does it will be before Thanksgiving of this year imo.

Worst part is, their development appears to actually HELP people

So why in the hell would the fda say, redo the trial vs
do a PH 4 follow up trial following approval.

Unfricking real..

Yeah, I sold out some years ago as well, held off taking a new position until recently.

Got a 1000 shares at $7.55, have $900 in profits off the covered calls. So going to keep doing that
while this gets figured out. Only concern is whats going to happen to the value of the calls as this
quiets down.. Might be tough to get a lot for them.

Yep, have seen enough out of the fda to again, realize its integrity has been compromised.. And that
IS NOT a good thing..

But sadly, its just a reflection of the overall breakdown in morals, ethics, integrity, honesty in this world now.
Replaced by the desire for GREED and POWER no matter what gets sacrificed to get it.

Thank you for your reply which confirms my feelings regarding FDA’s lack of integrity surrounding the approval process. I’m happy that I sold about half of my position a couple of years ago (at around 12). I guess we wait for an unsatisfying buyout?

Yep, thats my understanding as well. They concurred in the trial, which means they
had agreed on the 'acceptance' criteria.

But at least this explains WHY its taken them so long to announce filing for approval.

And been a long time observer/concluder that the FDA doesn't have the publics best
interest as their primary goal. Figured it out some years ago that big pharma runs the
fda, guides its 'decisions'.

Even to the point where I have suspected that new ideas trying that are 'targets' by
a big pharma who would like to own the idea, may find it harder to get to their end point.
To the point they become illiquid and forced to 'negotiate' just so that the developers can
get something for their efforts.

Or even worse, in this case, since this does appear to HELP people going thru treatment,
that despite this conclusion, the fda doesn't give a damn that it does. And once again, instead
of saying, we will approve but you have to do a PH 4 followup to conclude just how well it works.
We are going to flat out DENY the ones that could benefit from this from using it to help extend/save
their lives. Nope, we are going to endanger lives instead by DENYING them a potential treatment
that has shown it can help them. That to me is the really sick part of this mess.

Yep, sure appears to be a royal screw job. Not just for ATNM, but really for those that it could HELP.

I believe it was Astra Zenica buying Force Pharmaceuticals?

Actinium Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S.
Can they get approval outside the US?

Perhaps a new partner is on the bid…?
With deep pockets…
Did the drug makers pressure fda to force this?

Did some company like ABBV or ABT or GSK buy that other Actinium using company?

There are other companies that use the radio therapeutic actinium investigationally. FDA has approved its use in clinical trials to treat prostate, breast and other solid tissue cancers, but, I couldn’t find any information on any company that holds marketing approval.

Didn’t FDA just approve another company’s drug that also contained actinium?

I think they are mostly big pharma- centered. The deck is truly stacked against the smaller players. It’s a shame because most of the true innovation comes from the small guys!

FDA is a criminal agency. How could exert a pressure on patients not to cross over when it comes to life and death. FDA needs to use ECA and other documented data to compare and evaluate the results.

The message from the company is that they have to run a whole new trial (apparently without a cross over option)

Now what kind of test they want to run? Is it full trial size or what?

Wow. The FDA really screwed us on this one. One must question if the FDA really has the public’s interest in mind when making these decisions. If I’m understanding it correctly, FDA approved the SIERRA study, even went so far as to say that it would be enough to garner approval, then decided that it wasn’t enough to file a BLA?

fda just screwed ATNM over by telling them the trials acceptance criteria (which the FDA 'accepted' when the trial was
put together) needs to be changed.

https://ir.actiniumpharma.com/press-releases/detail/486

Would like to see them get their NDA submitted already.

Be nice to see them advancing their first product to market to start generating

some revenues.

For everything else they are 'spending' cash on is years from generating revenue unless

its good enough for them to be bought out or gain a partnership.

Today’s news was interesting in that atnm Will start on path developing new method to treat sickle cell cases. This will have the attention of.Vertex as an alternative to chemo. VRTX is working with CRSP on their first approved treatment using CRSPR TECHNOLOGY for sickle disease . It would be quite nice for.ATNM to rub shoulders withVRTX and CRSP as they have very deep pockets! Might pull in those calls LOL

LOL...

Nope, been a while since I was serious about holding shares for the NDA submission.

But noticed the calls have some 'value' to them, and also that accumulation occurred in

APRIL, MAY and its happening again now. (have a sentiment indicator I monitor on the

charting software I use)..

Should actually send a message to their IR and ask them to update folks on their

NDA submission status. Like what in the heck is taking so long (smile)

Not much posting here, so you are the one buying all the shares to take it to $10?

Thank you

No really it is moving up nicely

Started my accumulation of shares this morn.

But also selling covered calls on the shares while I wait.

Got shares at $7.55 and sold the Sept $10 Strike price for .55 cents/..

good way to get some gains, hopefully hold onto the shares in the process.

Good luck.

Oddly 5400 volume after hours.

Something is up with this one.

The time to be in is right before close on Friday. News could be over the weekend and Monday morning nice gap and run.

ATNM with BLA news, should realistically hit 30 dollars minimum in multiple days.